Antiangiogenic gene therapy in inhibition of metastasis.

• Authors: Stanisław Szala , Jarosław Szary , Tomasz Cichoń , Aleksander Sochanik
• Languages of publication: EN

Abstracts

EN

This short review attempts to demonstrate the usefulness of antiangiogenic gene therapy in achieving inhibition of growth in experimentally-induced metastases. Certain normal tissues (for example skeletal muscle) may be used in vivo, after genetic modification, as a "bioreactor", able to produce and secrete into the bloodstream proteins known to exert antiangiogenic effects. By inhibiting neoangiogenesis these proteins would thus prevent the development of metastases. The review discusses also the perspectives of antimetastatic therapy based on certain types of allogenic cells (for example myoblasts and fibroblasts) that had been genetically modified and then microencapsulated. The strategy of encapsulation is aimed at protecting the modified cells secreting antiangiogenic factors from being eliminated by the immune system. Secretion of antiangiogenic proteins by these microencapsulated cells can be controlled with inducible promoters. Antiangiogenic genes remaining under the transcriptional control of such promoters may be switched on and off using antibiotics, such as tetracycline derivatives, or steroid hormones.

Keywords

EN

antiangiogenic gene therapy; encapsulation; inducible gene expression; metastasis

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2002
• Volume: 49
• Issue: 2
• Pages: 313-321

Dates

published

2002

received

2001-11-12

revised

2002-04-22

accepted

2002-05-29

Contributors

author

Stanisław Szala

• Department of Molecular Biology, Center of Oncology - Maria Skłodowska-Curie Memorial Institute, Gliwice, Poland

author

Jarosław Szary

• Department of Molecular Biology, Center of Oncology - Maria Skłodowska-Curie Memorial Institute, Gliwice, Poland

author

Tomasz Cichoń

• Department of Molecular Biology, Center of Oncology - Maria Skłodowska-Curie Memorial Institute, Gliwice, Poland

author

Aleksander Sochanik

• Department of Molecular Biology, Center of Oncology - Maria Skłodowska-Curie Memorial Institute, Gliwice, Poland

References

• Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. (2000) Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med.; 6: 100-2.
• Bachoud-Lévi A-C, Déglon N, Nguyen J-P, Bloch J, Bourdet C, Winkel L, Rémy P, Goddard M, Lefaucheur J-P, Brugiéres P, Baudic S, Cesaro P, Peschanski M, Aebischer P. (2000) Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther.; 11: 1723-9.
• Bani MR, Giavazzi R. (2000) Invasion and metastasis. In Principles of molecular oncology. Bronchud MH, Foote MA, Peters WP, Robinson MO. eds, pp 297-321. Humana Press Inc, Totowa, NJ.
• Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W. (1999) Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol.; 17: 343-8.
• Brauker J, Frost GH, Dwarki V, Nijjar T, Chin R, Carr-Brendel V, Jasunas C, Hodgett D, Stone W, Cohen LK, Johnson RC. (1998) Sustained expression of high levels of human factor IX from human cells implanted within an immunoisolation device into anthymic rodents. Hum Gene Ther.; 9: 879-88.
• Chambers AF, MacDonald IC, Schmidt EE, Morris VL, Groom AC. (2000) Clinical targets for anti-metastasis therapy. Adv Cancer Res.; 79: 91-121.
• Chen CT, Lin J, Li Q, Phipps SS, Jakubczak JL, Stewart DA, Skripchenko Y, Forry-Schaudies S, Wood J, Schnell C, Hallenbeck PL. (2000) Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther.; 11: 1983-96.
• Clark EA, Golub TR, Lander ES, Hynes RO. (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature.; 406: 532-5.
• Condeelis JS, Wyckoff J, Segall JE. (2000) Imaging of cancer invasion and metastasis using green fluorescent protein. Eur J Cancer.; 36: 1671-80.
• Dalle B, Payen E, Regulier E, Deglon N, Rouyer-Fessard P, Beuzard Y, Aebischer P. (1999) Improvement of mouse β-thalassemia upon erythropoietin delivery by encapsulated myoblasts. Gene Ther.; 6: 157-61.
• Dimitroff CJ, Sharma A, Bernacki RJ. (1998) Cancer metastasis: a search for therapeutic inhibition. Cancer Invest.; 16: 279-90.
• Engers R, Gabbert HE. (2000) Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol.; 126: 682-92.
• Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM. (2001) Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A.; 98: 1853-8.
• Feldman AL, Libutti SK. (2000) Progress in antiangiogenic gene therapy of cancer. Cancer.; 89: 1181-94.
• Folkman J. (1996) New perspectives in clinical oncology from angiogenesis research. Eur J Cancer.; 32A: 2534-9.
• Folkman J. (1998) Antiangiogenic gene therapy. Proc Natl Acad Sci U S A.; 95: 9064-6.
• Fussenegger M. (2001) The impact of mammalian gene regulation concepts on functional genomic research, metabolic engineering, and advanced gene therapies. Biotechnol Prog.; 17: 1-15.
• Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Bernhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobart P, Norman J, Manthorpe M. (1996) An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther.; 7: 1205-17.
• Holmgren L, O'Reilly MS, Folkman J. (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med.; 1: 149-53.
• Hortelano G, Xu N, Vandenberg A, Solera J, Chang PL, Ofosu FA. (1999) Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules. Hum Gene Ther.; 10: 1281-8.
• Kim YJ, Borsig L, Varki NM, Varki A. (1998) P-selection deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA.; 95: 9325-30.
• Kong H-L, Crystal RG. (1998) Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst.; 90: 273-86.
• Liotta LA, Stetler-Stevenson WG. (1993) Principles of molecular cell biology of cancer: cancer metastasis. In Cancer: principles & practice of oncology. DeVita, Jr VT, Hellman, S, Rosenberg SA. eds, pp 134-49. JP Lippincott Co, Philadephia.
• Löhr M, Müller P, Karle P, Stange J, Mitzner S, Jesnowski R, Nizze H, Nebe B, Liebe S, Salmons B, Günzburg WH. (1998) Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther.; 5: 1070-8.
• Maxwell IH, Cripe TP. (2000) Transcriptional targeting. Tumor Targeting.; 4: 189-209.
• McDonnell CO, Hill ADK, McNamara DA, Walsh TN, Bouchier-Hayes DJ. (2000) Tumour micrometastases: the influence of angiogenesis. Eur J Surg Oncol.; 26: 105-15.
• Miller N, Whelan J. (1997) Progress in transcriptionally target and regulatable vectors for genetic therapy. Hum Gene Ther.; 8: 803-15.
• Mir LM. (2000) Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry; 53: 1-10.
• Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, Mcclanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Varástegui E, Zlotnik A. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature.; 410: 50-6.
• O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell.; 88: 277-85.
• Serguera C, Bohl D, Rolland E, Prevost P, Heard JM. (1999) Control of erythropoietin secretion by doxycycline or mifepristone on mice bearing polymer-encapsulated engineered cells. Hum Gene Ther.; 10: 375-83.
• Sim BKL, MacDonald NJ, Gubish ER. (2000) Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev.; 19: 181-90.
• Szary J, Szala S. (2001) Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth. Int J Cancer.; 91: 835-39.
• Taguchi A, Blood DC, Del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori OS, Ogawa S, Stern SM, Schmidt AM. (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature.; 405: 354-60.
• Tanaka M, Kogawa K, Nakamura K, Nishihori Y, Kuribayashi K, Hagiwara S, Muramatsu H, Sakamaki S, Niitsu Y. (2001) Anti-metastatic gene therapy utilizing subcutaneous inoculation of EC-SOD gene transduced autologous fibroblast suppressed lung metastasis of Meth-A cells and 3LL cells in mice. Gene Ther.; 8: 149-56.
• Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, Al-Mehdi AB, Bernhard EJ, Muschel RJ. (2001) Apoptosis: an early event in metastatic inefficiency. Cancer Res.; 61: 333-8.